Skip to content
MedsAcross

Medicine

Tregzi kit

Available on requestPrescription onlyUS FDA Cold chain

Tregzi kit is a prescription medicine containing Allogeneic regulatory t cell immunotherapy with hspc and T cells, marketed by Orca Biosystems, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Cold chain

Store the Tregs and HSPCs in refrigerated storage at 2°C to 8°C (36°F to 46°F)…

Key facts

Active ingredient (INN)
Allogeneic regulatory t cell immunotherapy with hspc and T cells
Brand
Tregzi
Dosage form
Kit
Packs
1 kit
Marketing authorisation holder
Orca Biosystems
Manufacturer
Orca Biosystems
Origin register
US FDA, United States
Storage
Store the Tregs and HSPCs in refrigerated storage at 2°C to 8°C (36°F to 46°F) until the time of use. Per institutional guidelines, Tregs and HSPCs may be kept in shipping container or moved to refrigerated storage up to the expiry time. Do not freeze. Cryopreserved TREGZI Tcons The Tcons are shipped frozen in vapor phase of liquid nitrogen at below -125°C (below -193°F).
Cold chain
Yes, shipped temperature controlled
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3002.51Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
30 June 2026
Identifiers
RxCUI 2747373, 2747379DailyMed set ID 2157e11b-87c3-4d54-a225-81b341e4e21aNDC 85866-223Application BLA125868

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 kit in 1 carton * 100 mL in 1 bag * 1 bag in 1 cartridge / 15 mL in 1 bag * 1 bag in 1 carton / 30 mL in 1 bag * 100 mL in 1 bag85866-223-04Orca Biosystems30 June 2026

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Clinical summary

Allogeneic regulatory t cell immunotherapy with hspc and T cells is a fixed-dose combination medicine. It is available as kits. MedsAcross supplies Allogeneic regulatory t cell immunotherapy with hspc and T cells for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Allogeneic regulatory t cell immunotherapy with hspc and T cells

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Tregzi kit for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.